Effective measures for the primary<unk>  of sudden<unk>  death in individuals who are at risk of SCD but have not yet experienced an aborted<unk><unk>  or life-threatening arrhythmias include ICD implantation based on the guideline. Secondary<unk>  strategy following aborted sudden<unk>  death include revascularization in patients with ischemic heart disease and  ICD implantation in patients with reduced left ventricular ejection fraction who had an experience of lethal arrhythmia.
The optimal approach to<unk>  of SCD following ST-elevation MI (STEMI) has been evaluated in multiple randomized trials. In general,<unk> -STEMI patients should be treated with evidence-based therapies that have been associated with a reduction in SCD including beta-blockers, ACE-inhibitors (or ARBs in patients who are ACEI intolerant) and statins. In patients who have symptomatic congestive heart failure (CHF), an aldosterone antagonist may be a reasonable additional therapy. Despite the intuitive benefits of antiarrhythmic, amiodarone and sotalol have not been shown to reduce all-cause mortality following STEMI, although amiodarone may be useful in reducing the frequency of shocks in patients with ICDs who have unacceptably high rates of shock. In general terms, ICD placement is indicated in those patients with a reduced left ventricular ejection fraction at 40 days<unk> -MI and/or 3 months following revascularization (PCI or CABG) for STEMI given the survival benefits in this population.
Sudden cardiac death post arrest care and prevention
Sudden cardiac death definitions and diagnosis
Congestive heart failure end-of-life considerations
Traumatic brain injury future or investigational therapies
Endocarditis long term care
Reperfusion injury future or investigational therapies
Congestive heart failure treatment of special populations
Traumatic brain injury primary prevention